9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Familial Dysalbuminemic Hyperthyroxinemia and Thyroid Hormone Autoantibodies: Interference in Current Free Thyroid Hormone Assays

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The interference of familial dysalbuminemic hyperthyroxinemia (FDH), antithyroxine (anti-T<sub>4</sub>) or antitriiodothyronine (anti-T<sub>3</sub>) antibodies in serum free T<sub>4</sub> (FT<sub>4</sub>) or free T<sub>3</sub> (FT<sub>3</sub>) assays depends on the assay method: two-step immunoextraction, one-step labelled ligand (analogue or derivative tracer) or labelled antibody (solid-phase antigen-linked technique: SPALT) method. For FDH subjects, only FT<sub>4</sub> measurements by one two-step method gave reliable results in all cases. However, the overestimation was less marked with new SPALT assays than with previous analogue-based assays. In sera containing anti-T<sub>4</sub> antibodies, two-step assays and SPALT assays with a T<sub>3</sub>-coated solid phase can be considered as reliable for FT<sub>4</sub> determination. All other methods including SPALT assays with a T<sub>4</sub>-coated solid phase may give falsely high results. In sera containing anti-T<sub>3</sub> antibodies, SPALT FT<sub>4</sub> and FT<sub>3</sub> assays with a T<sub>3</sub>-coated solid phase may give spuriously high values. Anti-T<sub>3</sub> antibodies do not interfere in two-step FT<sub>3</sub> assays and SPALT FT<sub>3</sub> assays with a T<sub>2</sub>-coated solid phase, but may give high FT<sub>3</sub> values as measured by analogue or derivative methods. Moreover, SPALT free thyroid hormone assays may also be subject to interference from antibodies directed towards the assay solid phase.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-6290-4
          978-3-318-00047-4
          1663-2818
          1663-2826
          1996
          1996
          09 December 2008
          : 45
          : 3-5
          : 139-141
          Affiliations
          aInstitut de Physique Biologique, Faculté de Médecine, et bPôle d’Endocrino-Diabéto-Nutrition, Service de Médecine Interne, Hôpital de Hautepierre, Strasbourg, France
          Article
          184776 Horm Res 1996;45:139–141
          10.1159/000184776
          8964572
          0bce1e27-429f-4c54-ad45-8c11e7b23f9b
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 3
          Categories
          Hormone Binding Proteins: Physiology and Clinical Implications

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Antitriiodothyronine autoantibodies,Familial dysalbuminemic hyperthyroxinemia,Interference,Free triiodothyronine assay,Antithyroxine autoantibodies,Free thyroxine assay

          Comments

          Comment on this article